Androgen deprivation and thromboembolic events in men with prostate cancer

Androgen deprivation therapy (ADT) improves prostate cancer outcomes in specific clinical settings, but is associated with adverse effects, including cardiac complications and possibly thromboembolic complications. The objective of this study was to estimate the impact of ADT on thromboembolic events (TEs) in a population‐based cohort.

[1]  D. G. Wagle.  Reimbursement policy and androgen-deprivation therapy for prostate cancer. , 2011, The New England journal of medicine.

[2]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[3]  A. Renshaw,et al.  Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. , 2010, International journal of radiation oncology, biology, physics.

[4]  Jonathan E. Dickerson,et al.  Supplementary Webappendix , 2022 .

[5]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[6]  G. Lippi,et al.  Prostate-specific antigen, prostate cancer, and disorders of hemostasis. , 2009, Seminars in thrombosis and hemostasis.

[7]  A. Kibel.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer , 2008 .

[8]  C. Nelson,et al.  Cognitive effects of hormone therapy in men with prostate cancer , 2008, Cancer.

[9]  E. Klein,et al.  Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population , 2008, Cancer.

[10]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[12]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[13]  U. Roggenbuck,et al.  Intraoperative and Early Postoperative Complications of Radical Retropubic Prostatectomy , 2007, Urologia Internationalis.

[14]  A. D'Amico,et al.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. D'Amico,et al.  Short‐ vs long‐term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node‐negative high‐risk adenocarcinoma of the prostate , 2007, Cancer.

[16]  D. Nathan,et al.  Insulin sensitivity during combined androgen blockade for prostate cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[18]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[19]  P. Walsh.  6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial , 2005 .

[20]  G. Chatta.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 , 2004 .

[21]  A. Varki,et al.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. , 2003, The Journal of clinical investigation.

[22]  J. Chin,et al.  Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. , 2003, The Journal of urology.

[23]  M. Cooperberg,et al.  National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[24]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[25]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[26]  S. Cerutti,et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. , 2002, The Journal of urology.

[27]  J. Stanford,et al.  Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. , 2002, Journal of the National Cancer Institute.

[28]  Anthony L Zietman,et al.  Changes in body composition during androgen deprivation therapy for prostate cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  M. Parmar,et al.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[30]  A. Falanga,et al.  Molecular basis for the relationship between thrombosis and cancer. , 2001, Thrombosis research.

[31]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[32]  T. Lue,et al.  Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. , 2000, Urology.

[33]  P. Bray,et al.  Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. , 2000, Blood.

[34]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[35]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.

[36]  M. Hammar,et al.  Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. , 1994, The Journal of urology.

[37]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[38]  Michael C. Minnotte,et al.  Noncancer deaths in white adult cancer patients. , 1993, Journal of the National Cancer Institute.

[39]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[40]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2012, Journal of the National Cancer Institute.

[41]  Miriam Lopez Gomez,et al.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients , 2008, Cancer.

[42]  Xiaoying Li,et al.  Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. , 2007, Thrombosis research.

[43]  A. Kibel.  Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer , 2007 .

[44]  Robert C. Wolpert,et al.  A Review of the , 1985 .